To the full analysis
Buyback calculator for BioCryst Pharmaceuticals
BioCryst Pharmaceuticals stock: key metrics
BCRXBioCryst Pharmaceuticals had an operating margin of 39% and a return on invested capital (ROIC) of 98.4% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2006 | 100.0% | −756.3% | −702.2% |
| 2007 | 100.0% | −45.3% | −40.8% |
| 2008 | 100.0% | −48.0% | −43.7% |
| 2009 | 93.9% | −18.4% | −18.0% |
| 2010 | 99.9% | −52.3% | −51.5% |
| 2011 | 100.0% | −252.4% | −289.9% |
| 2012 | 99.5% | −128.9% | −148.6% |
| 2013 | 99.4% | −177.2% | −173.7% |
| 2014 | 99.1% | −336.4% | −332.1% |
| 2015 | 96.1% | −81.7% | −89.1% |
| 2016 | 89.8% | −184.4% | −209.3% |
| 2017 | 93.2% | −227.9% | −261.2% |
| 2018 | 97.7% | −456.2% | −490.3% |
| 2019 | 91.6% | −203.7% | −223.0% |
| 2020 | 90.6% | −981.1% | −1,026.4% |
| 2021 | 95.4% | −113.1% | −117.1% |
| 2022 | 97.6% | −54.8% | −91.2% |
| 2023 | 98.6% | −31.3% | −68.4% |
| 2024 | 97.2% | −0.6% | −19.7% |
| 2025 | 97.8% | 39.0% | 30.2% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2006 | −100.0% | −64.3% | −63.7% |
| 2007 | −44.8% | −29.6% | −20.4% |
| 2008 | −53.3% | −23.6% | −29.2% |
| 2009 | −15.6% | −12.6% | −9.5% |
| 2010 | −49.1% | −28.0% | −29.6% |
| 2011 | −100.0% | −51.3% | −69.3% |
| 2012 | 10.0% | −48.6% | −68.0% |
| 2013 | 7.1% | −65.7% | −61.6% |
| 2014 | 9.7% | −50.6% | −33.0% |
| 2015 | 8.4% | −31.6% | −34.5% |
| 2016 | 9.7% | −50.6% | −61.4% |
| 2017 | 10.4% | −44.8% | −36.9% |
| 2018 | 13.8% | −59.6% | −69.0% |
| 2019 | −100.0% | −67.6% | −62.1% |
| 2020 | 200.0% | −72.5% | −54.6% |
| 2021 | 172.0% | −37.8% | −31.3% |
| 2022 | 83.9% | −25.2% | −44.9% |
| 2023 | 49.7% | −20.2% | −43.8% |
| 2024 | 18.7% | −0.5% | −18.1% |
| 2025 | −100.0% | 98.4% | 51.3% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 11 Sep 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.